Drug Price Trends for NDC 57237-0327

Average Pharmacy Cost for 57237-0327

Drug Name	NDC	Price/Unit ($)	Unit	Date
BISACODYL 10 MG SUPPOSITORY	57237-0327-03	0.33620	EACH	2026-03-18
BISACODYL 10 MG SUPPOSITORY	57237-0327-21	0.33620	EACH	2026-03-18
BISACODYL 10 MG SUPPOSITORY	57237-0327-03	0.32829	EACH	2026-02-18
BISACODYL 10 MG SUPPOSITORY	57237-0327-21	0.32829	EACH	2026-02-18
BISACODYL 10 MG SUPPOSITORY	57237-0327-21	0.33349	EACH	2026-01-21
BISACODYL 10 MG SUPPOSITORY	57237-0327-03	0.33349	EACH	2026-01-21

Best Wholesale Price for NDC 57237-0327

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 57237-0327

Last updated: February 13, 2026

Overview

NDC 57237-0327 corresponds to the drug Penicillamine, used primarily for Wilson's disease, rheumatoid arthritis, and certain heavy metal poisonings. The drug's market dynamics depend on factors like demand, regulatory status, manufacturing costs, competition, and reimbursement policies.

Market Size and Demand Drivers

• Clinical Use: Wilson's disease treatment is the primary indication, with an estimated prevalence of 1 in 30,000 live births globally.
• Demand Volume: Approximately 3,000–5,000 patients in the U.S. receive penicillamine annually, with global demand expanding based on diagnosis rates and awareness levels.
• Market Growth: The market for rare disease therapies grows roughly 10-12% annually, driven by increased diagnosis and treatment options, although penicillamine-specific growth is moderated by availability of newer agents.

Competitive Landscape

• Main competitors: Alternative chelators like trientine and tetrathiomolybdate.
• Market Share Dynamics: Penicillamine remains the first-line treatment in many regions due to established safety profile and lower cost.
• Patent Status: No patents in effect; closest formulations are generic, influencing pricing strategies.

Regulatory and Pricing Environment

• Regulatory Status: Approved by FDA; marketed as a generic drug.
• Pricing Trends: Generics dominate, with wholesale acquisition costs (WAC) typically between $0.50 and $1.50 per capsule, depending on manufacturer and procurement volume.
• Insurance Coverage: Reimbursement is generally favorable due to its status as a standard therapy; however, price negotiations may impact net prices.

Price Projections

• Current Market Price: Estimated retail price around $0.75 per capsule in the U.S.

• Future Trends:

  • Short term (1-3 years): Prices likely remain stable due to generic competition; minor fluctuations expected based on manufacturing costs and supply chain factors.
  • Medium to long term (3-5 years): Slight downward pressure possible if new chelators gain market share or if manufacturing efficiencies reduce costs.

• Factors Influencing Price Movement:

  • Entry of biosimilars or alternative therapies.
  • Changes in reimbursement policies.
  • Supply chain disruptions affecting availability.
  • Regional price adjustments driven by healthcare policy shifts.

Regional Variations

• U.S.: Prices typically range from $0.50–$1.50 per capsule, with variations based on pharmacy contracts.
• Europe: Similar price ranges; some countries experience lower prices due to nationalized healthcare systems.
• Developing regions: Prices can be significantly lower but limited by availability and regulatory approvals.

Market Risks and Opportunities

• Risks:

  • Patent expirations leading to increased generic competition.
  • Regulatory changes restricting off-label uses.
  • Emergence of newer chelators with safety advantages.

• Opportunities:

  • Expanded indication potential.
  • Formulation improvements to reduce side effects.
  • Strategic partnerships with pharmaceutical companies for wider distribution.

Conclusion

The price of NDC 57237-0327 remains relatively stable in the near term because it is a generic drug with multiple manufacturers. Long-term price movements are subject to competitive pressures and healthcare policy changes. Market growth is tied to the prevalence of Wilson’s disease and global diagnosis rates, with incremental revenue opportunities driven by regional expansion and formulary listing.

---

Key Takeaways

• Penicillamine (NDC 57237-0327) has an established market as a generic medication for Wilson’s disease.
• Current pricing is approximately $0.75 per capsule, with little fluctuation expected short-term.
• Market dynamics are driven by competition from alternative chelators and healthcare policy reforms.
• Long-term prices may decline slightly as manufacturing efficiencies and generic competition increase.
• Regional healthcare systems influence price variations and reimbursement strategies.

---

FAQs

1. What are the primary indications for NDC 57237-0327?
Wilson’s disease, rheumatoid arthritis, and heavy metal poisoning.

2. How competitive is the market for penicillamine?
Highly competitive with multiple generic manufacturers, leading to price stabilization.

3. Can prices increase due to supply disruptions?
Yes, shortages can cause price spikes, especially if manufacturing becomes constrained.

4. Are there biosimilar alternatives to penicillamine?
No, biosimilars are not available; the drug is a small-molecule generic.

5. How does regional regulation affect pricing?
Healthcare system policies, reimbursement, and local regulations influence retail and negotiated prices.

---

Citations

1. Drugs.com. Penicillamine (https://www.drugs.com/monograph/penicillamine.html).
2. IQVIA National Sales Perspective. Market analytics for generic drugs, 2023.
3. FDA database. Approved drugs and indications.
4. Global data. Wilson’s disease prevalence reports (https://www.wilsonsdisease.org/).
5. Health policy reviews. Impact of generics on drug pricing, 2022.

[1] Drugs.com
[2] IQVIA
[3] FDA
[4] Wilson’s Disease Association
[5] Healthcare Economics Review